Delving into the Latest Updates on Compound danshen dripping pills with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

compound danshen dripping pills

+ [3]

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [5]

Active Indication

Diabetic RetinopathyAngina PectorisAblepharon Macrostomia Syndrome+ [1]

Inactive Indication

Angina, StableBlood StasisNonproliferative diabetic retinopathy

Originator Organization

Tasly Pharmaceutical Group Co., Ltd.

Active Organization

Tasly Pharmaceutical Group Co., Ltd.Tasly Pharmaceuticals, Inc.

Inactive Organization

Arbor Pharmaceuticals LLC

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1994),

Angina Pectoris

Regulation-

Login to view timeline

This study is designed to evaluate the efficacy and safety of compound Danshen dropping pills (CDDP) in improving ventricular remodeling and cardiac function after acute anterior wall ST-Elevation myocardial infarction(STEMI). 268 patients with acute anterior wall STEMI after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to CDDP group(n=134) and control group(n=134) with follow-up of 24 weeks. Both groups are treated with standard therapy of STEMI, with the CDDP group administrating 20 tablets of CDDP before pPCI and 10 tablets three times a day after pPCI and the control group treated with placebo at the same time. The primary endpoint is 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI).The secondary endpoint is the change in N terminal pro-B-type natriuretic peptide（NT-proBNP ）level, arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).

Start Date25 Aug 2021

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

NCT04993729

/ CompletedPhase 3

A Multicenter, Double-blind, Randomized and Placebo-controlled Pivotal Phase 3 Study to Evaluate the Safety and Efficacy of T89 in the Prevention and Treatment of Acute Mountain Sickness (AMS) After Rapid Ascent

The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.

Start Date21 Jul 2021

Sponsor / Collaborator

Tasly Pharmaceuticals, Inc.

100 Clinical Results associated with Compound danshen dripping pills

Login to view more data

100 Translational Medicine associated with Compound danshen dripping pills

Login to view more data

100 Patents (Medical) associated with Compound danshen dripping pills

Login to view more data

12

Literatures (Medical) associated with Compound danshen dripping pills

01 Jan 2025·The Journal of Biomedical Research

Effect of Compound Danshen Dripping Pills on cardiac function after acute anterior ST-segment elevation myocardial infarction: A randomized trial

Article

Author: Gu, Shunzhong ; Wang, Li ; Wang, Liansheng ; Yu, Zongliang ; Qiao, Rui ; Wang, Sibo ; Wang, Qiming ; Zhang, Yuqing ; Deng, Bo ; Zhao, Shengbiao ; Yang, Yang ; Wu, Lixing ; Zhou, Shuanglin ; Lu, Yuan ; Zhang, Xiwen ; Li, Kaiqiao ; Wu, Yujie

The current study aimed to evaluate the efficacy and safety of Compound Danshen Dripping Pills (CDDP) in improving cardiac function among patients with acute anterior ST-segment elevation myocardial infarction (AAMI). Between February 2021 and February 2023, 247 eligible patients with AAMI after primary percutaneous coronary intervention (pPCI) were enrolled and randomly assigned (1∶1) to receive CDDP ( n = 126) or placebo ( n = 121), with a follow-up of 48 weeks. Compared with the placebo group, the CDDP group demonstrated a significant increase in left ventricular ejection fraction (LVEF) values after 24 weeks of the treatment (least squares mean: 3.31; 95% confidence interval [CI]: 1.72-4.90; P < 0.001) and at the 48-week follow-up (least squares mean: 4.35; 95% CI: 2.76-5.94; P < 0.001). Significant reductions of N-terminal pro-B-type natriuretic peptide levels were observed in both groups at the 24- and 48-week visits without difference between the two groups ( P > 0.1 for all), and 6.35% and 5.79% of patients in the CDDP and placebo groups experienced major adverse cardiovascular and cerebrovascular events, respectively ( P = 0.822). Therefore, no serious adverse events were attributed to CDDP. These findings sugget that CDDP was well tolerated and improved LVEF of patients with AAMI in 24 and 48 weeks.

01 Sep 2019·British Journal of Pharmacology

Tanshinol borneol ester, a novel synthetic small molecule angiogenesis stimulator inspired by botanical formulations for angina pectoris

Article

Author: Sun, Jiaxin ; Wu, Jingni ; Liu, Ruimin ; Zhang, Peng ; Zheng, Xiaohui ; Wang, Xin ; Li, Shao ; Zheng, Xiaopu ; Kang, Ximeng ; Fu, Youlan ; Liao, Sha ; Liu, Kechun ; Fan, Tai‐ping ; Han, Liwen

Background and PurposeTanshinol borneol ester (DBZ) is a novel synthetic compound derived from Dantonic®, a botanical drug approved in 26 countries outside the United States for angina pectoris and currently undergoing FDA Phase III clinical trial. Here, we investigated the angiogenic effects of (S)‐DBZ and (R)‐DBZ isomers in vitro and in vivo.Experimental ApproachA network pharmacology approach was used to predict molecular targets of DBZ. The effects of DBZ isomers on proliferation, migration, and tube formation of human endothelial cells were assessed. For in vivo approaches, the transgenic Tg (vegfr2:GFP) zebrafish and C57BL/6 mouse Matrigel plug models were used. ELISA and western blots were used to quantitate the release and expression of relevant target molecules and signalling pathways.Key ResultsDBZ produced a biphasic modulation on proliferation and migration of three types of human endothelial cells. Both DBZ isomers induced tube formation in Matrigel assay and a 12‐day co‐culture model in vitro. Moreover, DBZ promoted Matrigel neovascularization in mice and partially reversed the vascular disruption in zebrafish induced by PTK787. Mechanistically, DBZ enhanced the cellular levels of VEGF, VEGFR2, and MMP‐9, as well as activating Akt and MAPK signalling in endothelial cells. Selective inhibition of PI3K and MEK significantly attenuated its angiogenic effects.Conclusions and ImplicationsThese data reveal, for the first time, that DBZ promotes multiple key steps of angiogenesis, at least in part through Akt and MAPK signalling pathways, and suggest it may be potentially developed further for treating myocardial infarction and other cardiovascular diseases.

01 Jan 2019·Biomedicine & PharmacotherapyQ2 · MEDICINE

A review of the mechanism of action of Dantonic® for the treatment of chronic stable angina

Q2 · MEDICINE

Review

Author: Liao, Wenjing ; Li, Xinxin ; Ma, Xiaohui ; Sun, He ; Guo, Zhixin ; Li, Ju ; Zhou, Shuiping

Chronic stable angina (CSA) presents as a complication of coronary heart disease, leading to a high incidence and mortality rate worldwide. Dantonic^® or Compound Danshen Dripping Pills (CDDP) is a well-known traditional Chinese medicine used for the treatment of myocardial ischemic diseases, such as angina pectoris (AP), myocardial infarction, and sudden death. Dantonic^® has been extensively utilized in clinical practice in China for more than 14 years and has proved to be an effective therapy for the treatment of many myocardial ischemic diseases since its approval by CFDA in 1994. Clinical studies in China have shown that Dantonic^® is an effective and safe drug for the treatment of angina pectoris manifested with ameliorating anginal symptoms and showing few adverse effects. Nevertheless, the mechanism of Dantonic^® for the treatment of angina has been underestimated. Therefore, in this review, we mainly focus on discussing the pharmacological mechanism of action (MoA) of Dantonic^® for the treatment of CSA, including the promotion of coronary microcirculation, the optimization of myocardial energy metabolism, and the inhibition of platelet aggregation.

100 Deals associated with Compound danshen dripping pills

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetic Retinopathy	China	Tasly Pharmaceutical Group Co., Ltd.	15 Nov 2013
Angina Pectoris	South Africa	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	Russia	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	South Korea	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	Singapore	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	China	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	Mongolia	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994
Angina Pectoris	Vietnam	Tasly Pharmaceutical Group Co., Ltd.	01 Jan 1994

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina Pectoris	Discovery	United States	Arbor Pharmaceuticals LLC	06 Sep 2018
Blood Stasis	Discovery	China	Tasly Pharmaceuticals, Inc.	01 May 2013
Nonproliferative diabetic retinopathy	Discovery	China	Tasly Pharmaceuticals, Inc.	01 May 2013
Angina, Stable	Discovery	United States	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Discovery	Russia	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Discovery	Canada	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Discovery	Ukraine	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Discovery	Mexico	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Discovery	Georgia	Tasly Pharmaceuticals, Inc.	01 Aug 2012
Angina, Stable	Discovery	Belarus	Tasly Pharmaceuticals, Inc.	01 Aug 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01679028 (CTgov)	Phase 1	-	20	Placebo Group A (Placebo Group A)	jwtjzyxyva(gvhmjbjpac) = vswvoygukg vltmnswozl (fbsunrkoxz, pfhsflpxrd - kinbfautyc) View more	-	24 Nov 2014
				T89 Group A (T89 Group A)	jwtjzyxyva(gvhmjbjpac) = bigjwferwv vltmnswozl (fbsunrkoxz, hrjuwyskdk - cyldqwrypx) View more